Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Myeloid Malignancies
100%
Single-center Experience
100%
Mixed Donor chimerism
100%
Post-transplantation Cyclophosphamide (PTCy)
100%
Relapse-free Survival
37%
Graft-versus-host Disease (GvHD)
25%
High Risk
25%
Mixed chimerism
25%
Relapse Risk
25%
Disease Relapse
25%
Overall Survival
25%
Donor Cells
25%
Graft-versus-host Disease Prophylaxis
25%
Adverse Risk
25%
Risk Reduction
12%
Disease Risk
12%
Acute Myeloid Leukemia
12%
Myelodysplastic Syndrome
12%
Electronic Health Records
12%
Patient Characteristics
12%
Multivariable
12%
Prognostic Factors
12%
Disease Pattern
12%
Myeloablative Conditioning
12%
Unrelated Donor Transplantation
12%
Graft-versus-leukemia Effect
12%
Predictive Value
12%
Disease Status
12%
Minimal Residual Disease
12%
Low Dose Rate
12%
Non-associated
12%
Unrelated Donor
12%
Large Cohort
12%
Underlying Disease
12%
Recipient Cells
12%
Hematopoietic Cell Transplantation-specific Comorbidity Index
12%
Relapsed Disease
12%
Mixed Disease
12%
Single-center Study
12%
Medicine and Dentistry
Myeloid Malignancy
100%
Cyclophosphamide
100%
Allogeneic Hematopoietic Stem Cell Transplantation
100%
Diseases
62%
Recurrence Free Survival
37%
Acute Myelogenous Leukemia
25%
Chronic Graft Versus Host Disease
25%
Overall Survival
25%
Graft Versus Host Reaction
25%
Electronic Health Record
12%
Hematopoietic Cell
12%
Acute Myeloid Leukemia
12%
Cell Transplantation
12%
Myelodysplastic Syndrome
12%
Myeloablative Conditioning
12%
Minimal Residual Disease
12%
Graft Versus Tumor Effect
12%
Comorbidity
12%
Immunology and Microbiology
Myeloid
100%
Allogeneic Hematopoietic Stem Cell Transplantation
100%
Cyclophosphamide
100%
Recurrence Free Survival
37%
Graft-Versus-Host Disease
25%
Chronic Graft Versus Host Disease
25%
Overall Survival
25%
Cell Transplantation
12%
Conditioning
12%
Electronic Health Record
12%
Hematopoietic Cell
12%
Graft Versus Tumor Effect
12%
Comorbidity
12%
Pharmacology, Toxicology and Pharmaceutical Science
Cyclophosphamide
100%
Diseases
71%
Recurrence Free Survival
42%
Graft Versus Host Reaction
28%
Chronic Graft Versus Host Disease
28%
Overall Survival
28%
Neoplasm
14%
Myelodysplastic Syndrome
14%
Acute Myeloid Leukemia
14%
Minimal Residual Disease
14%
Comorbidity
14%